Decitabine in older patients with AML; EPCR and sickle chronic kidney disease; lymphocyte depletion versus post-transplant cyclophosphamide for mismatched donor transplant for inborn errors of immunity

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

2026-09-24- KSR - Hour 1 1h 4m · 24 Sep 2026 · KSR

Football vs jetlag | Who is the Mayo of the NFL? | Super Bowl favourites | Hockey's coaching scandal | US Sports Roundtable 1h 11m · 24 Sep 2026 · Indo Sport

Is This The October Surprise? (Ep. 2602) 1h 30m · 24 Sep 2026 · The Dan Bongino Show

Sage Advice From Granny Bingo 19 min · 24 Sep 2026 · It's A Lot with Abbie Chatfield

Trump, Xi Begin State Visit, Oil Soars on Iran Threat, More 7 min · 24 Sep 2026 · Bloomberg News Now

The Single Dumbest Thing Ever Said About the Miami Heat | Hour 2 37 min · 24 Sep 2026 · The Dan Le Batard Show

Report any issue

Source

Recorded01 Aug 2024

Publisherfeeds.transistor.fm ↗

Handlerec:11741957

Show notes

In this week's episode we’ll discuss the safety and efficacy of decitabine in older patients with AML; learn how heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice, and discuss the outcomes of treatment with HLA-mismatched HSCT with TCRab/CD19 lymphocyte depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Featured Articles:Decitabine in older patients with AML: Quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase III trial Heme induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice Outcomes of HLA-mismatched HSCT with TCRab/CD19 depletion or post-HSCT cyclophosphamide for inborn errors or immunity

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in